20 April 2022Jurisdiction reportsNaomi Pearce and Katrina Crooks

Australia: Achieving early generic/biosimilar market entry

These developments provide a swift and cost-effective path to remove patent barriers to generic/biosimilar market entry in Australia, where the market formation date is determined by an extended patent.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Patents

Australia reverses DABUS AI inventorship ruling

13 April 2022 The Federal Court of Australia has overturned its prior ruling that artificial intelligence (AI) can be a named inventor on a patent application, striking down the last year’s surprising win for Stephen Thaler and his ongoing AI inventorship campaign.

Patents

DABUS: decoding Australia’s AI decision

10 August 2021 Allowing an AI as an inventor could benefit the country’s pharma and drug discovery industries, say Richard Hamer, Lauren John and Alexandra Moloney of Allens.

UK firms Venner Shipley and AA Thornton combine

UPC docs 'excessively redacted' under GDPR claims transparency lawyer

L'Oréal sued over virtual makeup try-on simulator

Kathi Vidal to leave USPTO ahead of incoming Trump administration

Q&A: EagleView counsel maps out route to IPR victory

WIPO in Saudi Arabia to finalise design law treaty

Douwe Egberts enjoys double shot over Nestlé in coffee patent rivalry

Startup CFO’s betrayal is a lesson in preparing for the worst

Australia: Achieving early generic/biosimilar market entry

More on this story

Editor's picks

Editor's picks

More articles